Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients.
To assess the relationship between the Thrombolytic Assessment System (TAS); (Cardiovascular Diagnostics, Inc, Raleigh, NC) measurements and heparin levels in cardiac surgical patients. Equipment evaluation in vitro and in vivo. A university teaching hospital. Sixty adult patients undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB). Part 1: Simultaneous heparin management tests (HMTs) and activated coagulation times (ACTs) were measured in 20 patients pre-CPB, during CPB, and post-CPB. In the same patients, the effect of heparin, 1 to 5 IU/mL, on the HMT was assessed in vitro. The effect of aprotinin, 50 to 200 KIU/mL, on the HMT, was assessed in vitro in a further 10 patients. Part II: Simultaneous TAS and laboratory (LAB) activated partial thromboplastin times (APTTs) were measured pre-CPB and post-CPB in 20 patients. In the same patients, the effect of heparin, 0.1 to 0.5 IU/mL, on the TAS APTT was assessed in vitro. The effect of aprotinin on the TAS APTT was assessed in vitro in a further 10 patients. Part I: Heparin, 0, 1, 2, and 5 IU/mL in vitro resulted in HMTs of 164 +/- 12, 281 +/- 19, 338 +/- 16, and 436 +/- 33 seconds (mean +/- standard deviation [SD]), respectively. The HMT had less variability than the ACT in vivo. Part II: Heparin, 0, 0.1, 0.2, and 0.5 IU/mL in vitro, resulted in TAS APTTs of 34.9 +/- 4.7, 61.2 +/- 2.5, 97.4 +/- 34.7, and 197.1 +/- 64.3 seconds, respectively. The correlation (r) between the TAS and LAB APTT was 0.726 pre-CPB and 0.794 post-CPB. Aprotinin increased both the HMT and TAS APTT in a dose-related manner. The TAS may be a useful monitor of heparin effect in cardiac surgical patients.